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Abstract
Background and Objectives The retrospective compari-
son of test and reference treatment arms in a randomized
prospective clinical trial is potentially useful in economic
modeling seeking to assess the cost effectiveness of alter-
native therapies.
Methods To enhance the credibility of such retrospective
comparisons, we propose the application of the following
adjustments to significance levels obtained from standard
statistical methodology: (1) a significance test for the lower
bound of the 95 % confidence interval for the observed
difference, (2) a conservative Bonferroni method of
adjustment for multiple comparisons, (3) an adjusted
p-value calculated using Scheffe’s single-step method, and
(4) Bayesian 95 % credibility intervals with a prior cen-
tered at zero.
Results These adjustments were applied to data from a
randomized double-blind concurrent trial (SPD489-325)
that established the efficacy and safety of lisdexamfetamine
dimesylate (LDX) in children and adolescents with atten-
tion-deficit/hyperactivity disorder (ADHD). Prospectively
planned analyses demonstrated that the reduction in the
symptoms of ADHD was significantly greater than placebo
in patients treated with either LDX or the reference treat-
ment, osmotic-release oral system methylphenidate
(OROS-MPH). Retrospective analyses showed that the
improvement in the symptoms of ADHD was greater in
patients treated with LDX than OROS-MPH. We now
show that this observation remained significant after the
application of the four statistical penalties.
Conclusions By adjusting the significance level, it is
possible to compare quantitatively such retrospective
results with prospectively defined comparisons. However,
the qualitative level of such retrospective evidence should
remain secondary to that obtained from prospectively
specified comparisons in a randomized clinical trial.
Key Points
To improve credibility of retrospective comparisons
in randomized clinical trials, we propose four
statistical methods to discount the observed p-value
or 95 % confidence interval to account for the
retrospective nature of the analysis
Potentially useful retrospective results are currently
not available because of a lack of appropriate
standardization methodology that can allow
comparison to prospective results. The proposed
methods provide a tool for such comparisons
1 Introduction
Prospectively posing the research hypotheses along with
the design of the experiment, as well as defining the
methods for data analysis, are at the heart of scientific
research methods. A well-designed clinical trial protocol
should clearly state the statistical hypotheses and statistical
tests planned, and provide a power analysis to determine
the adequacy of the proposed sample size to achieve the
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predetermined study goals. The purpose of this prescribed
approach is to ensure integrity and prevent bias in the
scientific development process. Clinical trials, however,
often generate additional information that fall outside the
bounds of the planned analyses but that may be of value in
clinical, formulary, and reimbursement decision making.
In considering control groups for pivotal clinical trials,
regulators typically require the test drug to demonstrate
superiority to placebo. In addition, the inclusion of a third
arm consisting of a gold-standard reference therapy is
considered optimal [1–3]. The purpose of the parallel
comparison of a reference treatment with placebo is to
provide evidence of the validity and sensitivity of the study
design and execution [1–3]. However, once the predefined
comparison of the experimental drug with placebo has been
conducted in such a three-arm trial, and the efficacy of the
reference treatment compared with placebo has established
the validity and sensitivity of the study design and execu-
tion, the question arises if it is acceptable to compare the
test and reference arms retrospectively. A review of clini-
caltrials.gov identified 79 interventional, placebo-con-
trolled, phase III studies in any therapy area, completed
(with results) since the beginning of 2010 and that included
an active reference arm. Thus, clinical trials that include a
reference arm as well as test and placebo arms are not
uncommon and the retrospective comparison of test and
reference therapies is potentially a rich source of clinically
useful information. However, when not predefined, such a
comparison of active treatment arms is controversial. One
concern is the risk of publication bias (i.e., the tendency to
publish only positive results), and one might argue that
such unplanned retrospective findings should never be
accepted for publication. A second concern is that phar-
maceutical companies, which are obligated to report study
findings per protocol to government agencies, could avoid
pre-specifying more ‘risky’ comparisons to avoid having to
report unfavorable findings. However, when the primary
endpoint data for the reference treatment are collected
under exactly the same conditions as the test drug, a ret-
rospective comparison of active treatment arms may be
informative and of value. Indeed, given the cost and delay
involved in conducting an additional, head-to-head, ran-
domized clinical trial, the retrospective comparison of the
two active treatments in a three-arm clinical trial may
provide the only means to compare the test drug with a
standard therapy of known efficacy and safety and, when
used appropriately, may advance the understanding of how
a medicine performs and support decision making by
payers seeking to establish policy for the reimbursement of
alternative treatments.
In the present paper, we suggest that confidence in ret-
rospective comparisons of active treatments in multi-arm
clinical trials may be increased by imposing statistical
penalties designed to raise the threshold for such unplanned
analyses to be considered ‘statistically significant’. We
describe four ‘penalty’ methods and apply them to the
retrospective comparison of the two active treatment arms
in study SPD489-325 [4, 5]. This was a randomized,
double-blind, dose-optimized, placebo-controlled, phase III
trial of the prodrug stimulant lisdexamfetamine dimesylate
(LDX) in children and adolescents with attention-deficit/
hyperactivity disorder (ADHD), which included a refer-
ence arm of the standard therapy, osmotic-release oral
system methylphenidate (OROS-MPH).
2 Methods
2.1 Adjusting Significance Levels from Standard
Retrospective Comparisons
It is assumed that the active treatment arms to be compared
retrospectively were part of a randomized and well-con-
trolled clinical trial, and that the reference treatment was a
standard therapy of known efficacy and safety. Intuitively,
when analyzing clinical trial results retrospectively, the
probability of a type I error should be anywhere between
the achieved p-value, ignoring the fact that the test was not
prospectively defined, and the maximal value of one.
Stating this from a confidence level viewpoint, the level of
confidence we require from this result should be at least
95 % (as it would be if the test was proposed prospec-
tively). This logic suggests that, in addition to clearly
labeling results that were retrospectively proposed, the
strategy for interpreting this evidence should be based on a
penalty for its retrospective nature. We describe four
methods of ‘adjusting’ the significance level and confi-
dence in the observed difference between two active
treatment arms from randomized clinical trials to account
for the retrospective nature of the analyses. Obviously, for
the adjustments to be meaningful, the outcome of the
conventional analysis must be statistically significant
because the adjustments are designed to reduce the level of
significance from that observed prior to the adjustments.
2.1.1 Method 1: Significance Test for the Lower Bound
of the 95 % Confidence Interval for the Observed
Difference
The observed difference and confidence level used (95 %)
in the retrospective test defines a confidence interval (CI).
Without loss of generality, we assume that the observed
point estimate for the difference between treatments is
negative (i.e., a negative difference indicates improvement
for the test treatment compared with the reference). Then,
the upper bound for a negative difference that is closer to
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zero can be thought of as the ‘worst-case scenario’ for the
observed difference that is consistent with the alternative
hypothesis. Assuming that the upper bound of such a 95 %
CI is the observed point estimate for the difference, then a
one-sided test of significance to assess if the lower bound is
less than zero, using the original test statistic denominator
will result in a more conservative test than the one that
would be prospectively defined.
2.1.2 Method 2: Simultaneous Testing Procedures
If the comparative test had been proposed prospectively, it
could have been tested at the standard significance level
used in the study for the rest of the primary objective tests.
However, given that the comparison was proposed retro-
spectively, this no longer applies and a more stringent
significance level is required. One way to recalculate the
significance level for this test could be to view this situa-
tion as having added a secondary ad hoc test whose results
should be adjusted for multiple comparisons using a fam-
ily-wise level. This method has a built-in objective mech-
anism to determine how low the new significance level
should be to accept the evidence from the retrospective
comparative test.
There are several options for a single-step family-wise
adjustment of the significance level. We suggest the highly
conservative Bonferroni method [6]. This method requires
that the family-wise error is divided amongst the planned
comparisons, e.g., a three-arm study with three possible
pairwise comparisons tested at 5 % (two-sided) would
require an adjustment such that each pairwise comparison
is compared with p = 0.017.
2.1.3 Method 3: Adjusted p-Values
Results from the simultaneous test procedures suggested in
Method 2 may be more intuitively understood if, instead of
adjusting the significance level, adjusted p-values are
reported [7]. This method is similar to Method 2 and works
by restating the unadjusted p-value based on its relation-
ship to the adjusted significance level. For example, for the
single-step Bonferroni (B) and Sidak (S) methods we have
P Bð Þadj¼ n  Punadj ð1Þ
and
P Sð Þadj¼ 1 1Punadj
 n
; ð2Þ
where n is the number of hypotheses being tested. For
Scheffe’s single-step method, the unadjusted p-value is
found by calculating the ratio of the comparison sum of
squares (SSc) over the mean square error and finding the
tail of an F distribution with 1 and (N-g) degrees of
freedom, where g is the number of tests and N the total
sample size. The adjusted p-value is found by calculating
the F statistic as the ratio of SSc/(g-1) over the mean
square error and finding the tail of an F distribution with
(g-1) and (N-1) degrees of freedom. Multistage proce-
dures may be applied to obtain more powerful results than
the classic procedures. For this study, the authors have
chosen Scheffe’s single-step method.
2.1.4 Method 4: Bayesian 95 % Credibility Intervals
The Bayesian method proposed by Matthews can be used
to assess quantitative credibility, taking explicit account of
prior insights and experience. In our case, the prior infor-
mation can be used as a penalty for the retrospective nature
of the comparison. To this end, we shall apply a prior
distribution consistent with the null hypothesis of ‘no dif-
ference between treatments’. For convenience, a normal
prior will be used for the primary comparison between the
test and reference drugs. Mean and variance parameters for
the prior normal distribution may be obtained from pub-
lished results on comparisons between the drugs. As there
is no prior information in the literature on the difference
between the study and reference arm drugs in our example,
we illustrate the method using a prior normal distribution
centered at zero (no difference between the drugs) and also
find the threshold prior mean value needed to maintain a
significant advantage for the study drug. The same variance
for the difference between the study and reference arms
found in study SPD489-325 is used in the absence of a
better prior estimate.
Given an observed 95 % CI for the treatment difference
LD; UD½  ¼ XD  1:96 SD ð3Þ
Bayes’s Theorem provides the means of combining
evidence captured as a prior distribution. Using a normal
prior distribution, the result is a posterior distribution
expressed in the form of a credible interval [LP, UP] in
which
LP; UP½  ¼ XP  1:96 SP ð4Þ
with SP and XP calculated from
ð1=SPÞ ¼ ð1=S0Þ þ ð1=SDÞ ð5Þ
and
ð XP=SPÞ ¼ ð X0=S0Þ þ ð XD=SDÞ ð6Þ
For the results to be credible, the posterior 95 %
credibility interval [LP, UP] should still show an advantage
for the test drug.
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2.2 SPD489-325: A Randomized, Double-blind,
Placebo- and Active-controlled Clinical Trial
To explore the implications of the above penalty methods,
we applied them to results obtained from a randomized,
double-blind, placebo- and active-controlled clinical trial
(SPD489-325) of LDX in children and adolescents with
ADHD [4, 5]. The study was conducted in accordance with
current applicable regulations and the standards of good
clinical practice. The primary endpoint was the change
from baseline to endpoint in ADHD symptoms measured
using the ADHD Rating Scale IV (ADHD-RS-IV) total
score [8]. This scale is derived from the 18 inattentive and
hyperactive/impulsive diagnostic criteria for ADHD in the
Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition [9]. The range of the scale is 0–54 and a
reduction in score indicates an improvement in ADHD
symptoms. The study was powered to show a difference
between each active treatment and placebo and the pre-
specified comparisons were between LDX and placebo and
between OROS-MPH and placebo, adjusted for baseline
ADHD-RS-IV total score, age group (6–12, 13–17 years),
and country (nine European countries). Least-squares
means were estimated for each of the treatment arms and
for the differences between treatment arms using an ana-
lysis of covariance model. A formal statistical test was not
pre-specified between LDX and OROS-MPH. The ran-
domization and blinding procedures, data collection and
monitoring, data double-entry, logical checks, and query-
ing were all done prospectively, in a uniform manner
irrespective of the fact that the comparison between the two
active drugs was not planned in the protocol, and with the
same level of scrutiny in accordance with the study spon-
sor’s standard operating procedures. OROS-MPH, the ref-
erence treatment in this study, is a long-acting
methylphenidate formulation of well-established efficacy
and safety [10, 11], and is approved for the treatment of
children, adolescents, and adults with ADHD [12].
3 Results
In the primary outcome from study SPD489-325, reduc-
tions in the ADHD-RS-IV total score were significantly
greater in patients treated with LDX (N = 104) or OROS-
MPH (N = 107) than in those who received placebo
(N = 106) [4]. The estimated least-squares mean change
(standard error) in ADHD-RS-IV scores from baseline to
study endpoint for the LDX, OROS-MPH, and placebo
groups were -24.30 (1.16), -18.72 (1.14), and -5.70
(1.13), respectively [4]. The planned comparisons between
each treatment arm and placebo were statistically signifi-
cant and are provided in Table 1. When tested
retrospectively, it was found that the improvement in
symptoms of ADHD was significantly greater for LDX
than OROS-MPH (Table 1) [5]. The impact of the four
methods for adjusting the outcome of this retrospective
comparison will now be assessed.
3.1 Method 1: 95 % CI Lower Bound
The 95 % CI bound for the LDX vs OROS-MPH differ-
ence in adjusted mean change from baseline ADHD-RS-IV
score was -8.45, -2.70. Using the upper bound of the
95 % CI to represent the worst-case scenario for the mean
difference between active treatment groups, the new p-
value from a significance test that the upper bound mean
difference (-2.70) is less than zero is 0.034. This result
supports a statistically significant improvement in patients
receiving LDX compared with OROS-MPH.
3.2 Method 2: Simultaneous Testing Procedure
Using the conservative Bonferroni method of adjustment
for multiple comparisons, we obtain a p-value significance
cut-off of 0.017 instead of 0.05. With an observed p-value
of 0.0002 for the retrospective comparison of the two
active treatment arms, a statistically significant improve-
ment in patients receiving LDX compared with OROS-
MPH is still supported in the presence of the adjustment.
3.3 Method 3: Adjusted p-Values
The adjusted p-value calculated using Scheffe’s single-step
method was found by calculating the F statistic as the ratio
of SSc/2 over the mean square error and finding the tail of
an F distribution with (2) and (302) degrees of freedom. In
this case, the adjusted p-value equals 0.027, indicating that
the improvement in patients treated with LDX was statis-
tically significantly greater than in those who received
OROS-MPH.
3.4 Method 4: Bayesian 95 % Credibility Intervals
In SPD489-325, the 95 % CI for the difference between
LDX and OROS-MPH in least-squares mean ADHD-RS
total score was -8.45, -2.70 [5]. Using a normal prior
distribution with a mean of zero and a standard deviation of
1.46, we calculated the posterior standard deviation SP to
be 0.73 and the posterior 95 % credibility interval to be
-4.22, -1.35, indicating that LDX was significantly more
effective than OROS-MPH despite this adjustment. The
threshold value for the prior distribution mean difference
between LDX and OROS-MPH was 2.75, namely an
ADHD-RS-IV total score advantage of OROS-MPH by
2.75 units.
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3.5 Comparison of Methods
In general, Method 1 would result in the strictest penalty
for conducting the comparison of the test and reference
treatments retrospectively. Based on this method, we first
create a 95 % CI for the mean difference between treat-
ments and consider the CI bound closer to zero, that is a
shift from the CI midpoint of about 1.96 standard errors.
The penalty involves shifting another 1.64 standard errors
towards zero by testing the difference of this new point
from zero using a one-sided test. This is equivalent to
requiring a minimum difference of 3.6 standard errors from
zero for the observed mean difference between treatments,
or a significance level of about 0.0002.
Methods 2 and 3 will generally coincide in their con-
clusion, as Method 2 calculates a penalized significance
level and Method 3 calculated an adjusted p-value based on
similar multiple statistical comparisons methodology. For
the typical three-arm clinical trial, the resulting cut-off
p-value is 0.017, not nearly as restrictive as Method 1.
For Method 4, the degree of penalty can vary depending
on the prior distribution used. Clearly, the more distant
towards the opposite side of zero the prior mean is relative
to the observed mean difference between treatments, the
smaller the prior variance value and the larger the sample
size for the source of the prior information, the stronger the
prior evidence against the observed results and the stricter
the penalty. Figure 1 presents a sensitivity analysis of the
credibility intervals as the mean and standard deviation of
the assumed prior distribution are varied.
4 Discussion
We propose that the application of statistical penalties to
the outcomes of a retrospective comparison of test and
reference therapies in a three-arm clinical trial will add to
the credibility of the analysis when used to aid decision
making by, for example, formularies and payers. The
unplanned retrospective comparisons of the two active
treatments in a randomized, double-blind, dose-optimized,
placebo- and active-controlled, phase III trial of LDX in
children and adolescents with ADHD (SPD489-325) con-
cluded that the reduction in symptoms was statistically
significantly greater in the LDX group than in the active
OROS-MPH group [5]. We now report that the difference
between the two active treatments remains statistically
significant when four different statistical penalties are
Table 1 Change in ADHD-RS-IV total score from baseline to study endpointa: comparison between treatment arms in study SPD489-325 [4, 5]
Comparison Difference in least-squares means Standard error 95 % CI for difference p-value
LDX vs. placebo (planned) -18.60 1.456 (-21.47, -15.74) \0.0001
OROS-MPH vs. placebo (planned) -13.03 1.436 (-15.85, -10.20) \0.0001
LDX vs. OROS-MPH (retrospective) -5.57 1.460 (-8.45, -2.70) 0.0002
ADHD-RS-IV ADHD Rating Scale IV, CI confidence interval, LDX lisdexamfetamine dimesylate, OROS-MPH osmotic-release oral system
methylphenidate
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Fig. 1 Sensitivity analysis of the 95 % Bayesian credibility intervals
(Method 4) over mean and standard deviation of the prior distribution.
CI credibility interval, SD standard deviation
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applied, suggesting that the findings from this retrospective
comparison are robust.
Although controversial, retrospective analyses of
experimental data can yield useful information beyond the
predefined objectives of a study. One approach to the ret-
rospective analysis of clinical trial data is a meta-analysis,
a standard well-established method for the integration of
summary statistics (e.g., effect size, standard errors, and
sample sizes) across trials. Typically, such analyses pool
results from similarly designed, comparative clinical trials.
However, one of the major problems in combining findings
remains the weighting of data to reflect the accurate ‘value
of information’ from each study. To address this issue,
DerSimonian and Laird [13] examined eight published
meta-analyses and proposed a method to assign trial
weights using a random effect size approach. A second
approach is the post hoc analysis of clinical trial data. Such
analyses may be used to discover new indications, partic-
ularly for unsuccessful compounds [14], combine patient
data from several clinical trials or apply other stratification
schemes [15], and combine clinical trial patient data with
other sources such as historical data [16]. In the above
examples, clinical trial information is used to address
questions that are external or broader than the goals of the
original trials and are, therefore, accepted as legitimate
reuse of the data.
In the specific case of study SPD489-325, the compar-
ison of test and reference arm was not pre-specified.
However, the clinical trial was conducted in a manner that
would have allowed for the comparison of the LDX and
OROS-MPH treatment arms had that comparison been pre-
specified. The reference arm data used in the retrospective
comparison are of equal quality to those of the protocol-
specified analyses because the study was a randomized
double-blind trial such that treatment was unknown. No
modifications were made to the design or conduct of this
study because this test was not planned, and all of the
required information has been collected and is available.
Moreover, the retrospective comparison of test and refer-
ence therapies is informative because it includes all of the
information about the treatment effect available in the
study sample. For these reasons, we argue that the methods
of analysis that should have been used to compare active
treatments had the comparison been prospectively planned
can still be applied. This is in marked contrast to the ret-
rospective statistical analyses of subgroups in which the
post hoc definition of subgroups of interest can be a source
of bias, outcomes are strongly influenced by the size of the
subgroups, and which usually involve multiple hypothesis
testing [17–19].
To improve the credibility of the retrospective statistical
comparison of treatment arms in clinical trials such as
SPD489-325, we suggest that the results of the analysis be
discounted compared with results obtained from hypothe-
ses tested prospectively. To achieve this, we have proposed
four statistical methods to penalize the observed p value or
95 % CI to account for the retrospective nature of the
analysis. In the example of study SPD489-325, the retro-
spective comparison of test and reference therapies indi-
cated that symptomatic improvements based on ADHD-
RS-IV total scores were significantly greater in patients
receiving LDX than OROS-MPH [5]. This comparison
remained statistically significant when each of the four
penalty methods were applied: (1) using a significance test
for the upper bound of the 95 % CI for the observed dif-
ference (p = 0.034), (2) using a conservative Bonferroni
method of adjustment for multiple comparisons
(p \ 0.017), (3) using an adjusted p value calculated using
Scheffe’s single-step method (p = 0.027), and (4) using a
Bayesian 95 % credibility interval with a prior centred at
zero (-4.22, -1.35). These results are strongly supportive
of statistical significance for the retrospective comparison
of LDX and OROS-MPH in study SPD489-325.
For results to remain significant after adjustment, the
unadjusted comparison should typically be highly signifi-
cant. In other words, the results should be indicative of a
strong difference in treatment efficacy or based on a large
sample or both. Clearly, the impact of the penalties will
depend on how strongly significant was the observed ret-
rospective p value: the four methods suggested here are
dependent on the mean and standard error of the observed
difference between the test treatment and the reference
treatment arms. In addition, Methods 2 and 3 depend on the
number of additional multiple comparisons conducted
while Method 4 depends on the prior distribution specifi-
cation. Given the conceptual difference in the approach for
applying a penalty on the observed significance of the
retrospective comparison between Method 1, Methods 2
and 3, and Method 4, the conclusions from the methods
may diverge, particularly when the observed retrospective
comparison p-value is only moderately significant. There is
no single gold standard method or sequence of methods we
recommend using and for a particular situation only a
single method of penalized testing needs to be applied. In
our example, we applied all four methods for illustrative
purposes. The choice of the method should be transparent.
The choice between a frequentist or Bayesian analysis
method is subjective and may depend on the availability of
reliable and useful prior information. Choosing between a
more conservative approach such as Method 1 or less
restrictive ones such as Methods 2 or 3 may depend on the
level of risk involved with the decision, similar to the
dilemma regarding the determination of a type I error level.
The difficulties that arise with the retrospective statis-
tical comparison of data obtained from prospective clinical
trials are publication bias and the interpretation of the
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findings. Regarding publication bias, clinical trial sponsors
are required to report on the results of the prospectively
approved treatment comparisons, but not on unplanned
retrospective ones. For the type of trial with a test treat-
ment, reference treatment, and placebo arms, sponsors are
required to report on the comparisons with the placebo
arm. Because there is no standard framework for publica-
tion of the retrospective comparison of test and reference
treatments, these results are currently not likely to be
published, which may lead the reader to conclude, perhaps
erroneously, that there was no difference between test and
reference treatment arms. If the suggested penalty meth-
odology is accepted it will provide a platform for the
publication of such comparisons.
As for the interpretation of such findings, this type of
statistical evidence is a hybrid between a prospective
controlled clinical trial and a retrospective analysis, in
which the data are from the former and the inference is
from the latter. In this scenario, because the data are
obtained in a controlled randomized setting, they are as
reliable as in standard randomized clinical trials. However,
it is clear that we have a lower level of confidence in the
significance of retrospective comparisons than those
obtained a priori planned comparisons using controlled
clinical trial data. Results obtained with unplanned com-
parisons should always be disclosed as such and judged
with caution. We suggest that the qualitative value of the
evidence obtained from such hybrid comparisons be clas-
sified between evidence from prospective randomized
clinical trials and that from retrospective studies with non-
randomized data.
Although we argue that unplanned comparisons of active
treatment arms from a randomized clinical trial can be tested
credibly, especially when statistical outcomes are dis-
counted to account for their retrospective nature, it is
important to consider any potential clinical or biological
caveats of performing such a comparison. Do, for example,
the selected dose(s) and frequency of administration, study
duration, or study outcomes unduly favor one treatment over
another? In the case of SPD489-325, the authors of the
original undiscounted retrospective comparison of the active
treatment arms took care to discuss whether the fact that the
maximum permitted dose of the reference therapy OROS-
MPH in the European countries in which the trial was con-
ducted was lower than that permitted in North America may
have impacted the outcome of the comparison [5].
5 Conclusions
Concerns related to the retrospective efficacy analyses
include publication bias and the possibility that only
positive results will be widely reported. However, we
conclude that the retrospective comparison of active
treatment arms in a randomized double-blind trial is
meaningful when the data used in the retrospective com-
parison are of equal quality to those of the protocol-spec-
ified analyses and when methods designed to penalize the
classical confidence or significance level are employed. Of
course, the qualitative level of such retrospective evidence
should remain secondary to that obtained from prospec-
tively formulated comparisons from a randomized clinical
trial.
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